Plus Therapeutics (PSTV) AI Stock Analysis

• Market Cap: $40.69M
• Dividend Yield: N/A
• Average Volume (3M): 13.10M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.40
• Revenue Growth: -8.16%
• EPS Growth: 22.44%
• Country: US
• Employees: 21
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.04
• Shares Outstanding: 178,371,230
• 10 Day Avg. Volume: 19,323,028
• 30 Day Avg. Volume: 13,101,680
• PEG Ratio: 0.01
• Price to Book (P/B): -0.85
• Price to Sales (P/S): 1.31
• P/FCF Ratio: -0.71
• Enterprise Value/Market Cap: 0.01
• Enterprise Value/Revenue: 0.10
• Enterprise Value/Gross Profit: 0.11
• Enterprise Value/Ebitda: -0.03
• 1Y Price Target: $7.17
• Price Target Upside: 1135.63% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: $0.22 ▼(-62.59% Downside)

The score is driven primarily by weak financial performance—large ongoing losses, sharply negative free cash flow, and continued funding risk despite low debt. Technicals also weigh on the score with a clear downtrend (price below key moving averages and negative MACD), only partially offset by oversold readings. Valuation support is limited because the company is loss-making (negative P/E) and no dividend yield is provided.

Positive Factors

Innovative Product Development

The focus on Rhenium-186 NanoLiposome for targeted cancer treatment positions Plus Therapeutics as an innovator in the biopharmaceutical sector, potentially leading to significant advancements in cancer therapy and long-term growth opportunities.

Strategic Subsidiary Launch

The launch of CNSide Diagnostic's test enhances Plus Therapeutics' market presence in CNS cancer diagnosis, addressing unmet needs and potentially driving revenue growth through innovative diagnostic solutions.

Strategic Partnerships

The national coverage agreement with UnitedHealthcare could enhance market access and reimbursement for Plus Therapeutics' products, supporting long-term revenue stability and market penetration.

Negative Factors

Negative Equity

Negative equity indicates financial distress, limiting Plus Therapeutics' ability to raise capital and invest in growth, posing long-term risks to its financial health and operational sustainability.

Consistent Losses

Ongoing losses and lack of revenue generation highlight operational inefficiencies and financial instability, which could hinder Plus Therapeutics' ability to sustain its business model and achieve profitability.

Cash Flow Challenges

Negative cash flow from operations suggests inefficiencies and potential liquidity issues, impacting Plus Therapeutics' capacity to fund its R&D activities and strategic initiatives over the long term.

Plus Therapeutics Business Overview & Revenue Model

Company Description

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

How the Company Makes Money

Plus Therapeutics generates revenue primarily through the advancement of its product candidates into clinical trials, which may attract funding from partnerships, grants, and collaborations with pharmaceutical companies or research institutions. The company may also benefit from government grants and incentives for developing treatments that address significant health challenges. Additionally, once products receive regulatory approval, PSTV can generate revenue through product sales, licensing agreements, and potential royalties from partners. Strategic partnerships with larger pharmaceutical companies could enhance their financial stability by providing upfront payments and milestone payments tied to the successful development of their therapies.

Plus Therapeutics Financial Statement Overview

Summary

Very weak fundamentals: revenue is modest and highly volatile, profitability is deeply negative (TTM net margin about -391%) with negative EBIT/EBITDA, and cash burn is significant with materially negative TTM operating cash flow and free cash flow (~-$15.7M). Low debt helps, but the history of negative equity and continued funding needs keep financial risk elevated.

Income Statement

Revenue remains modest and volatile: TTM (Trailing-Twelve-Months) revenue declined 111% versus the prior period, following growth in 2024 and a sharp jump in 2023 off a low base. Profitability is the key weakness—TTM net margin is deeply negative (about -391%) with ongoing operating losses (negative EBIT and EBITDA), indicating the business is still far from breakeven despite a strong TTM gross margin (~89%).

Balance Sheet

Leverage looks low in the latest period (TTM total debt is minimal and debt-to-equity is near zero), which reduces near-term financial risk. However, equity has been unstable—stockholders’ equity was negative in 2023 and 2024 (a meaningful red flag), and return on equity metrics are inconsistent across periods, reflecting a company still dependent on external funding and subject to balance-sheet swings.

Cash Flow

Cash generation is weak and deteriorating: TTM operating cash flow and free cash flow are both materially negative (~-$15.7M), and TTM free cash flow declined sharply versus the prior period. While free cash flow roughly tracks reported losses (free cash flow to net income near 1), the core issue is the scale of ongoing cash burn, which likely necessitates additional financing if the trend persists.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.26M	5.82M	4.91M	224.00K	0.00	303.00K
Gross Profit	4.67M	4.97M	-4.78M	-488.00K	-66.00K	-2.40M
EBITDA	-16.14M	-8.40M	-12.69M	-18.85M	-12.05M	-8.44M
Net Income	-20.58M	-12.98M	-13.32M	-20.27M	-13.40M	-8.24M
Balance Sheet
Total Assets	18.67M	6.63M	11.39M	23.87M	21.98M	12.11M
Cash, Cash Equivalents and Short-Term Investments	13.29M	3.61M	8.55M	18.12M	18.40M	8.35M
Total Debt	21.00K	3.37M	4.18M	5.75M	6.99M	7.00M
Total Liabilities	13.62M	15.58M	12.74M	17.42M	11.14M	9.07M
Stockholders Equity	5.05M	-8.95M	-1.35M	6.45M	10.84M	3.03M
Cash Flow
Free Cash Flow	-15.78M	-10.70M	-13.01M	-13.73M	-10.42M	-8.93M
Operating Cash Flow	-15.73M	-10.55M	-12.85M	-12.97M	-10.28M	-8.43M
Investing Cash Flow	287.00K	-4.11M	-160.00K	-759.00K	-82.00K	-493.00K
Financing Cash Flow	27.51M	6.19M	3.44M	13.45M	20.42M	-319.00K

Plus Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.58
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PSTV, the sentiment is Negative. The current price of 0.58 is above the 20-day moving average (MA) of 0.38, above the 50-day MA of 0.51, and above the 200-day MA of 0.51, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 24.65 is Positive, neither overbought nor oversold. The STOCH value of 20.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PSTV.

Plus Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ACRV	49 Neutral	$56.48M	-0.84	-50.23%	―	―	21.17%
KPTI	48 Neutral	$119.38M	-0.45	―	―	-3.98%	-29.94%
SNTI	48 Neutral	$26.29M	-0.30	-394.62%	―	―	78.60%
TVRD	46 Neutral	$37.24M	-0.40	-97.61%	―	-53.67%	86.75%
BRNS	44 Neutral	$29.80M	-0.39	-62.30%	―	-100.00%	-26.30%
PSTV	40 Underperform	$40.69M	-0.12	―	―	-8.16%	22.44%

Plus Therapeutics Corporate Events

Plus Therapeutics Sharpens Focus on CNS Cancer Strategy

On January 22, 2026, Plus Therapeutics updated its corporate presentation for investors, outlining an intensified strategic focus on CNS cancers, an area where metastases now outnumber primary brain cancers by roughly ten to one and survival improvements have lagged for decades. The company highlighted CNSide as a “best-in-class” diagnostic for CNS metastases, backed by prior use at 120 U.S. institutions and recent national coverage agreements with major insurers, and detailed its lead radiotherapeutic candidate REYOBIQ, which is in multiple mid-stage ReSPECT clinical trials for leptomeningeal metastases and recurrent glioblastoma and is designed to deliver up to 20 times more radiation than standard therapies while bypassing the blood–brain barrier. By combining improved diagnostics, precision radiotherapeutics, and unified data analytics, Plus Therapeutics is seeking to create a new treatment “playbook” for CNS oncology, with the goal of materially extending median overall survival in leptomeningeal metastases and strengthening its competitive positioning in the growing CNS cancer market.

The most recent analyst rating on (PSTV) stock is a Hold with a $0.28 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.

Plus Therapeutics completes underwritten public equity offering

On January 13, 2026, Plus Therapeutics entered into an underwriting agreement with Lake Street Capital Markets for an underwritten public offering of 39,473,684 shares of common stock and an equal number of warrants at $0.38 per unit, with a 30-day option for additional shares and warrants to cover over-allotments, which the underwriter exercised on January 14, 2026 for 5,921,052 additional warrants. The offering, which closed on January 15, 2026, generated approximately $13.3 million in net proceeds that the company plans to use for working capital and general corporate purposes, and it is subject to a series of post-offering restrictions, including 45-day lock-ups on new equity issuance and insider sales and a 120-day ban on variable rate financing transactions, measures that collectively stabilize the capital structure in the near term while modestly diluting existing shareholders as Plus Therapeutics continues funding its CNS cancer programs.

The most recent analyst rating on (PSTV) stock is a Hold with a $0.28 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.

Plus Therapeutics Gains Nasdaq Extension for Compliance

On November 17, 2025, Plus Therapeutics announced it received an additional 180-day extension from Nasdaq to comply with the $1.00 minimum bid price requirement, extending the deadline to May 11, 2026. The extension allows Plus Therapeutics to continue trading on the Nasdaq Capital Market under the symbol ‘PSTV’ without immediate risk of delisting. The company is considering options, including a reverse stock split, to meet compliance, but there is no assurance of success. Failure to comply could result in delisting, which can be appealed.

The most recent analyst rating on (PSTV) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.